Jabbour on Tailoring Treatment With TKIs in CML and Ph+ ALL

Season 5 Episode 25  ·  Jul 19, 2021, 08:24 PM

Headliner
Share
Subscribe

Dr. Jabbour discusses the optimal use of ponatinib in chronic myeloid leukemia and data from the 2021 ASCO Annual Meeting with the combination of blinatumomab and ponatinib in Ph-positive acute lymphoblastic leukemia.

Share
Subscribe
Next
FDA Approval Insights: Sacituzumab Govitecan in Urothelial Cancer
Top episodes
DeNunzio Describes the Advantages of Proton Beam Therapy in Oncology
by OncLive® On Air
FDA Approval Insights: Amivantamab and Mobocertinib in EGFR Exon 20 Insertion+ NSCLC
by OncLive® On Air
Milhem Talks Mechanism of Action, Delivery Methodology, and Ongoing Trials With RP1
by OncLive® On Air